We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Evaluating the Ability of Zoledronic Acid to Reduce the Rate of Subsequent Osteoporotic Fractures After a Hip Fracture

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00046254
Recruitment Status : Completed
First Posted : September 25, 2002
Last Update Posted : May 2, 2012
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )

Brief Summary:
The purpose of this study is to evaluate whether zoledronic acid given once yearly for two years to men and women after surgical repair of a recent hip fracture will significantly reduce the rate of all re-occurring (new) osteoporotic fractures. All patients will receive vitamin D and calcium.

Condition or disease Intervention/treatment Phase
Osteoporosis Hip Fracture Drug: Zoledronic Acid Phase 3

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 2127 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Study Start Date : February 2002
Primary Completion Date : February 2007
Study Completion Date : February 2007

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Primary Outcome Measures :
  1. Significant reduction in rate of clinical fractures after surgical repair of hip fracture

Secondary Outcome Measures :
  1. Increase in total hip and femoral neck BMDs

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   50 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male or female ages 50 years or older
  • Must have a recent hip fracture repair in the past 90 days
  • Must be able to walk with or without assistive device (for example, using a walker) prior to the hip fracture

Exclusion Criteria:

  • Current bisphosphonate users such as aredia (pamidronate), didronel (etidronate), fosamax (alendronate), actonel (residronate), skelid (tiludronate)

Other protocol-defined inclusion/exclusion criteria may apply.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00046254

  Hide Study Locations
United States, Alabama
University of Alabama Hospital
Birmingham, Alabama, United States, 35294
United States, California
Osteoporosis Diagnostic Center
Eureka, California, United States, 95503
Sharp Grossmont Hosptial
La Mesa, California, United States, 91942
The Permanente Group
Santa Rosa, California, United States, 95403
United States, Florida
Radiant Research Lake Worth
Lake Worth, Florida, United States, 33461
United States, Georgia
Atlanta Resarch Center
Decatur, Georgia, United States, 30033
United Osteoporosis Center Health Services
Gainesville, Georgia, United States, 30501
United States, Illinois
Galesburg Orthopedic Services LTD
Galesburg, Illinois, United States, 61401
Illinois Bone and Joint Institute
Morton Grove, Illinois, United States, 60053
United States, Iowa
Mercy Arthritis and Osteoporosis Center
Des Moines, Iowa, United States, 50322
United States, Maine
Maine Medical Center Research Institute
Portland, Maine, United States, 04101
United States, Maryland
University of Maryland School of Medicine
Baltimore, Maryland, United States, 21201
United States, Michigan
Wayne State University, Div. of Endocrinology
Detroit, Michigan, United States, 48201
United States, Minnesota
Health East Osteoporosis Service
Woodbury, Minnesota, United States, 55125
United States, New York
Highland Hospital
Rochester, New York, United States, 14620
United States, North Carolina
University of North Carolina Hospital
Chapel Hill, North Carolina, United States, 27599
Duke University Health System
Durham, North Carolina, United States, 27710
United States, Ohio
University Orthopaedics
Canfield, Ohio, United States, 44406
Ohio State University
Columbus, Ohio, United States, 43210
United States, Pennsylvania
University of Pennsylvania Health System-Presbyterian Medical Center
Philadelphia, Pennsylvania, United States, 19104
Saint Joseph Medical Center
West Reading, Pennsylvania, United States, 19611
United States, Rhode Island
Saint Josephs
Warwick, Rhode Island, United States, 02818
United States, South Carolina
Palmetto Richland Memorial Hospital
Columbia, South Carolina, United States, 29203
United States, Texas
Seton Medical Center
Austin, Texas, United States, 78705
St. Luke's Episcopal Hospital
Houston, Texas, United States, 77030
United States, Virginia
Danville Regional Medical Center
Danville, Virginia, United States, 24541
United States, Wisconsin
University of Wisconsin Hospital and Clinics
Madison, Wisconsin, United States, 53706
Nuernberg, Germany
Sponsors and Collaborators
Novartis Pharmaceuticals

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Responsible Party: Novartis Pharmaceuticals
ClinicalTrials.gov Identifier: NCT00046254     History of Changes
Other Study ID Numbers: CZOL446H2310
First Posted: September 25, 2002    Key Record Dates
Last Update Posted: May 2, 2012
Last Verified: May 2012

Keywords provided by Novartis ( Novartis Pharmaceuticals ):
hip fracture
recurrent fracture
bone loss
bone mineral density
zoledronic acid
nursing home

Additional relevant MeSH terms:
Fractures, Bone
Hip Fractures
Osteoporotic Fractures
Wounds and Injuries
Bone Diseases, Metabolic
Bone Diseases
Musculoskeletal Diseases
Metabolic Diseases
Femoral Fractures
Hip Injuries
Leg Injuries
Zoledronic acid
Bone Density Conservation Agents
Physiological Effects of Drugs